ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$5.30 USD
-0.03 (-0.56%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $5.32 +0.02 (0.38%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CLPT 5.30 -0.03(-0.56%)
Will CLPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLPT
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
CLPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Other News for CLPT
ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons
ClearPoint Neuro congratulates Aspen Neuroscience on use of Navigation System
ClearPoint Neuro (CLPT) Receives a Buy from Lake Street